UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET ...
An update from Prophase Labs ( (PRPH) ) is now available.
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
Hosted on MSN
ProPhase Labs signals $50M net collection target and strategic initiatives as Crown Medical litigation advances
Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
ProPhase Labs is embarking on a significant financial restructuring, pivoting its strategy to bolster its balance sheet. The company has formally initiated the sale process for its esophageal cancer ...
UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a diversified diagnostics, genomics, and consumer healthcare company, today reported ...
ProPhase Labs develops and markets over-the-counter health supplements and diagnostic tools. Its product lineup includes dietary supplements for consumer health and the BE-Smart™ esophageal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results